Ignite Creation Date:
2025-12-25 @ 2:46 AM
Ignite Modification Date:
2026-04-19 @ 4:17 AM
Study NCT ID:
NCT02179333
Status:
COMPLETED
Last Update Posted:
2021-11-16
First Post:
2014-06-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)
Sponsor:
University of South Florida
Organization:
Study Overview
Official Title:
Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)
Status:
COMPLETED
Status Verified Date:
2021-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STAND
Brief Summary:
The objectives of this study are:
* To validate the inter-rater and intra-rater reliability of a new scale for the assessment of ataxia and neurologic dysfunction (STAND)
* To assess common constructs and correlation between STAND subscale items.
* To validate the inter-rater and intra-rater reliability of a new scale for the assessment of ataxia and neurologic dysfunction (STAND)
* To assess common constructs and correlation between STAND subscale items.
Detailed Description:
There are few validated, comprehensive rating scales for the assessment of ataxia severity. The development of a Scale To assess Ataxia and Neurologic Dysfunction (STAND) would examine and measure as many facets of ataxia as possible. Scale items to be measured include parkinsonism, timed gait analysis, dystonia, neuropathy and peripheral nerve weakness, as well as other areas of clinical manifestation for ataxia. This brief but thorough scale should yield a thorough measurement of ataxia.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: